Epigenetic regulation of the cell type-specific gene 14-3-3sigma. 2005

Marc M Oshiro, and Bernard W Futscher, and Aaron Lisberg, and Ryan J Wozniak, and Walter T Klimecki, and Frederick E Domann, and Anne E Cress
Pharmacology and Toxicology, University of Arizona, Arizona Cancer Center, Tucson, AZ 85724, USA.

Epigenetic control participates in processes crucial in mammalian development, such as X-chromosome inactivation, gene imprinting, and cell type-specific gene expression. We provide evidence that the p53-inducible gene 14-3-3sigma is a new example of a gene important to human cancer, where epigenetic mechanisms participate in the control of normal cell type-specific expression, as well as aberrant gene silencing in cancer cells. Like a previously identified cell type-specific gene maspin, 14-3-3sigma is a p53-inducible gene; however, it participates in G2/M arrest in response to DNA-damaging agents. 14-3-3Sigma expression is restricted to certain epithelial cell types, including breast and prostate, whereas expression is absent in nonepithelial tissues such as fibroblasts and lymphocytes. In this report, we show that in normal cells expressing 14-3-3sigma, the 14-3-3sigma CpG island is unmethylated; associated with acetylated histones, unmethylated histone H3 lysine 9; and an accessible chromatin structure. By contrast, normal cells that do not express 14-3-3sigma have a methylated 14-3-3sigma CpG island with hypoacetylated histones, methylated histone H3 lysine 9, and an inaccessible chromatin structure. These findings extend the spectrum of cell type-specific genes controlled, partly, by normal epigenetic mechanisms, and suggest that this subset of genes may represent important targets of epigenetic dysregulation in human cancer.

UI MeSH Term Description Entries
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011499 Protein Processing, Post-Translational Any of various enzymatically catalyzed post-translational modifications of PEPTIDES or PROTEINS in the cell of origin. These modifications include carboxylation; HYDROXYLATION; ACETYLATION; PHOSPHORYLATION; METHYLATION; GLYCOSYLATION; ubiquitination; oxidation; proteolysis; and crosslinking and result in changes in molecular weight and electrophoretic motility. Amino Acid Modification, Post-Translational,Post-Translational Modification,Post-Translational Protein Modification,Posttranslational Modification,Protein Modification, Post-Translational,Amino Acid Modification, Posttranslational,Post-Translational Amino Acid Modification,Post-Translational Modifications,Post-Translational Protein Processing,Posttranslational Amino Acid Modification,Posttranslational Modifications,Posttranslational Protein Processing,Protein Processing, Post Translational,Protein Processing, Posttranslational,Amino Acid Modification, Post Translational,Modification, Post-Translational,Modification, Post-Translational Protein,Modification, Posttranslational,Modifications, Post-Translational,Modifications, Post-Translational Protein,Modifications, Posttranslational,Post Translational Amino Acid Modification,Post Translational Modification,Post Translational Modifications,Post Translational Protein Modification,Post Translational Protein Processing,Post-Translational Protein Modifications,Processing, Post-Translational Protein,Processing, Posttranslational Protein,Protein Modification, Post Translational,Protein Modifications, Post-Translational
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002843 Chromatin The material of CHROMOSOMES. It is a complex of DNA; HISTONES; and nonhistone proteins (CHROMOSOMAL PROTEINS, NON-HISTONE) found within the nucleus of a cell. Chromatins
D005092 Exonucleases Enzymes that catalyze the release of mononucleotides by the hydrolysis of the terminal bond of deoxyribonucleotide or ribonucleotide chains. Exonuclease,3'-5'-Exonuclease,3'-5'-Exonucleases,5'-3'-Exonuclease,5'-3'-Exonucleases,3' 5' Exonuclease,3' 5' Exonucleases,5' 3' Exonuclease,5' 3' Exonucleases
D005095 Exoribonucleases A family of enzymes that catalyze the exonucleolytic cleavage of RNA. It includes EC 3.1.13.-, EC 3.1.14.-, EC 3.1.15.-, and EC 3.1.16.-. EC 3.1.- Exoribonuclease
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006657 Histones Small chromosomal proteins (approx 12-20 kD) possessing an open, unfolded structure and attached to the DNA in cell nuclei by ionic linkages. Classification into the various types (designated histone I, histone II, etc.) is based on the relative amounts of arginine and lysine in each. Histone,Histone H1,Histone H1(s),Histone H2a,Histone H2b,Histone H3,Histone H3.3,Histone H4,Histone H5,Histone H7
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000107 Acetylation Formation of an acetyl derivative. (Stedman, 25th ed) Acetylations

Related Publications

Marc M Oshiro, and Bernard W Futscher, and Aaron Lisberg, and Ryan J Wozniak, and Walter T Klimecki, and Frederick E Domann, and Anne E Cress
June 2006, Seminars in cancer biology,
Marc M Oshiro, and Bernard W Futscher, and Aaron Lisberg, and Ryan J Wozniak, and Walter T Klimecki, and Frederick E Domann, and Anne E Cress
January 2010, Molecular bioSystems,
Marc M Oshiro, and Bernard W Futscher, and Aaron Lisberg, and Ryan J Wozniak, and Walter T Klimecki, and Frederick E Domann, and Anne E Cress
April 2005, Cell research,
Marc M Oshiro, and Bernard W Futscher, and Aaron Lisberg, and Ryan J Wozniak, and Walter T Klimecki, and Frederick E Domann, and Anne E Cress
December 2004, Oncogene,
Marc M Oshiro, and Bernard W Futscher, and Aaron Lisberg, and Ryan J Wozniak, and Walter T Klimecki, and Frederick E Domann, and Anne E Cress
April 2002, Oncogene,
Marc M Oshiro, and Bernard W Futscher, and Aaron Lisberg, and Ryan J Wozniak, and Walter T Klimecki, and Frederick E Domann, and Anne E Cress
June 2006, Seminars in cancer biology,
Marc M Oshiro, and Bernard W Futscher, and Aaron Lisberg, and Ryan J Wozniak, and Walter T Klimecki, and Frederick E Domann, and Anne E Cress
May 2007, Ai zheng = Aizheng = Chinese journal of cancer,
Marc M Oshiro, and Bernard W Futscher, and Aaron Lisberg, and Ryan J Wozniak, and Walter T Klimecki, and Frederick E Domann, and Anne E Cress
December 2008, Clinical cancer research : an official journal of the American Association for Cancer Research,
Marc M Oshiro, and Bernard W Futscher, and Aaron Lisberg, and Ryan J Wozniak, and Walter T Klimecki, and Frederick E Domann, and Anne E Cress
January 2011, Proceedings of the National Academy of Sciences of the United States of America,
Marc M Oshiro, and Bernard W Futscher, and Aaron Lisberg, and Ryan J Wozniak, and Walter T Klimecki, and Frederick E Domann, and Anne E Cress
June 2009, Anticancer research,
Copied contents to your clipboard!